CoChat
Sign Up
Cited by 9Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma

Open access
Richardson, Paul G., Durie, Brian G., Rosiñol, Laura, Mateos, Maria-Victoria, Dispenzieri, Angela, Moreau, Philippe, Kumar, Shaji, Raje, Noopur, Munshi, Nikhil, Laubach, Jacob P., O’Gorman, Peter, O’Donnell, Elizabeth, Voorhees, Peter, Facon, Thierry, Bladé, Joan, Lonial, Sagar, Perrot, Aurore, Anderson, Kenneth C.·2023·Haematologica
DOI 10.3324/haematol.2022.282624PMC PMC10620581
Open this paper in CoChat — free accountOpen PDF

Abstract

To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients’ prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2022.282624

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several non-targeted drugs have been approved for MM treatment, including alkylating agents, corticosteroids, immunomodulatory imide drugs, proteasome inhibitors, histone deacetylase inhibitors, and XPO1 inhibitor.

    “Over the past few decades, several non-targeted drugs have been approved for the treatment of multiple myeloma, including alkylating agents [40], corticosteroids [41–43], immunomodulatory imide drugs (IMiDs) [44–47], proteasome inhibitors (PIs) [42, 48–51], histone deacetylases (iHDACs) inhibitors [37, 52, 53], and XPO1 inhibitor [54–56] (Table 1).”

    From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [43]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 88

  1. Gay F, Engelhardt M, Terpos E. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018; 103(2):197-211. · DOI
  2. Sonneveld P, Avet-Loiseau H, Lonial S. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016; 127(24):2955-2962. · DOI
  3. Kazandjian D, Mo CC, Landgren O, Richardson PG. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?. Br J Haematol. 2020; 191(5):692-703. · DOI
  4. Kumar SK, Dispenzieri A, Lacy MQ. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28(5):1122-1128. · DOI
  5. Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):508-517. · DOI
  6. Yong K, Delforge M, Driessen C. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016; 175(2):252-264. · DOI · Paper page
  7. Landgren O, Iskander K. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med. 2017; 281(4):365-382. · DOI
  8. Harousseau JL, Avet-Loiseau H, Attal M. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol. 2009; 27(34):5720-5726. · DOI
  9. Munshi NC, Avet-Loiseau H, Rawstron AC. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017; 3(1):28-35. · DOI
  10. Luptakova K, Rosenblatt J, Glotzbecker B. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013; 62(1):39-49. · DOI · Paper page
  11. Quach H, Ritchie D, Stewart AK. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22-32. · DOI
  12. Rajkumar SV, Jacobus S, Callander NS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11(1):29-37. · DOI · Paper page
  13. Hideshima T, Richardson P, Chauhan D. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61(7):3071-3076.
  14. Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Ann Oncol. 2010; 21(9):1756-1764. · DOI
  15. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011; 10(11):2034-2042. · DOI
  16. Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC. Bortezomib in multiple myeloma: systematic review and clinical considerations. Curr Oncol. 2014; 21(4):e573-603. · DOI
  17. Richardson PG, Weller E, Jagannath S. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009; 27(34):5713-5719. · DOI · Paper page
  18. Richardson PG, Xie W, Jagannath S. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014; 123(10):1461-1469. · DOI
  19. Delforge M, Terpos E, Richardson PG. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011; 86(5):372-384. · DOI
  20. Breitkreutz I, Raab MS, Vallet S. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008; 22(10):1925-1932. · DOI
  21. Jakubowiak AJ, Dytfeld D, Griffith KA. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012; 120(9):1801-1809. · DOI
  22. Kumar SK, Berdeja JG, Niesvizky R. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014; 15(13):1503-1512. · DOI
  23. Kubo K, Hori M, Ohta K. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan. Int J Hematol. 2020; 111(1):65-74. · DOI
  24. Richardson PG, Weller E, Lonial S. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010; 116(5):679-686. · DOI · Paper page
  25. Kumar S, Flinn I, Richardson PG. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012; 119(19):4375-4382. · DOI · Paper page
  26. Roussel M, Lauwers-Cances V, Robillard N. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014; 32(25):2712-2717. · DOI
  27. O'Donnell EK, Laubach JP, Yee AJ. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018; 182(2):222-230. · DOI
  28. Luoma S, Anttila P, Saily M. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group. Ann Hematol. 2019; 98(12):2781-2792. · DOI
  29. O'Gorman P, Laubach JP, O'Dwyer ME. Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma. Am J Hematol. 2022; 97(5):562-573. · DOI
  30. Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945. · DOI
  31. Voorhees PM, Kaufman JL, Laubach JP. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFIN study update Blood. 2020; 136(8):936-945.
  32. Bhutani M, Usmani SZ. Quadruplets come of age for newly diagnosed multiple myeloma. Lancet. 2020; 395(10218):94-96. · DOI
  33. Durie BGM, Hoering A, Abidi MH. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017; 389(10068):519-527. · DOI · Paper page
  34. Durie BGM, Hoering A, Sexton R. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020; 10(5):53. · DOI
  35. Durie BGM, Lam A, Ngo M, Pei H, Ammann EM. Post-hoc analysis of efficacy and safety in the SWOG S0777 trial stratified by age. Blood. 2022; 140(Suppl 1):10009-10010. · DOI
  36. Kumar SK, Jacobus SJ, Cohen AD. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21(10):1317-1330. · DOI
  37. Knop S, Langer C, Engelhardt MM. Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma. J Clin Oncol. 2017; 35(15_suppl):8001. · DOI
  38. Knop S, Langer C, Engelhardt MM. Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma. J Clin Oncol. 2020; 38(15):8521. · DOI
  39. Perrot A, Lauwers-Cances V, Cazaubiel T. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020; 136(Suppl 1):39. · DOI
  40. Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147. · DOI · Paper page
  41. Richardson PG, Jacobus SJ, Weller E. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): the phase 3 DETERMINATION trial. J Clin Oncol. 2022; 40(17_suppl):LBA4. · DOI
  42. Roussel M, Hebraud B, Hulin C. Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020; 61(6):1323-1333. · DOI
  43. Palacios JJL, Ubieto AJ, Rosiñol L. OAB-040: BUMEL vs MEL-200 prior autologous transplant for patients with newly diagnosed multiple myeloma previously treated with bortezomib, lenalidomide and dexamethasone: final results of a phase 3 trial. Clin Lymphoma Myeloma Leuk. 2022; 22:S24-S25. · DOI
  44. Cavo M, Tacchetti P, Patriarca F. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376(9758):2075-2085. · DOI
  45. Rosinol L, Hebraud B, Oriol A. Bortezomib-lenalidomide-dexamethasone vs bortezomib-thalidomide-dexamethasone induction: integrated analysis of randomized controlled trials in transplant-eligible newly diagnosed multiple myeloma. Hemasphere. 2019; 3(S1):249-250. · DOI
  46. Moreau P, Hulin C, Macro M. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016; 127(21):2569-2574. · DOI
  47. Rosinol L, Oriol A, Teruel AI. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012; 120(8):1589-1596. · DOI
  48. Harousseau JL, Attal M, Avet-Loiseau H. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010; 28(30):4621-4629. · DOI
  49. Punke AP, Waddell JA, Solimando DA. Lenalidomide, bortezomib, and dexamethasone (RVd) regimen for multiple myeloma. Hosp Pharm. 2017; 52(1):27-32. · DOI
  50. Mohan M, Matin A, Davies FE. Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res. 2017; 9:51-63. · DOI
  51. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies. JCO Oncol Pract. 2020; 16(2):56-66. · DOI
  52. Kumar SK, Laubach JP, Giove TJ. Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol. 2017; 178(5):756-763. · DOI
  53. Rodriguez C, Lantz J, Akbar F, Lantz L, Dressler E. Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/ dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2019; 19(10):E217-E218. · DOI
  54. Cook J, Johnson I, Higgins A. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021; 96(3):330-337. · DOI
  55. Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109. · DOI
  56. Joseph NS, Kaufman JL, Dhodapkar MV. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020; 38(17):1928-1937. · DOI · Paper page
  57. Jakubowiak AJ, Griffith KA, Reece DE. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011; 118(3):535-543. · DOI
  58. Voorhees PM, Rodriguez C, Reeves B. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Adv. 2021; 5(4):1092-1096. · DOI
  59. Mateos MV, Nahi H, Legiec W. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020; 7(5):e370-e380. · DOI
  60. Chari A, Rodriguez-Otero P, McCarthy H. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label phase II study. Br J Haematol. 2021; 192(5):869-878. · DOI
  61. Usmani SZ, Sexton R, Ailawadhi S. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015; 5(8):e334. · DOI
  62. Usmani SZ, Ailawadhi S, Sexton R. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). J Clin Oncol. 2020; 38(15):8507. · DOI
  63. Laubach J, Nooka AK, Cole C. An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma. J Clin Oncol. 2017; 35(15):8002. · DOI
  64. Ocio EM, Rodriguez Otero P, Bringhen S. Preliminary results from a phase i study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Blood. 2018; 132(Suppl 1):595. · DOI
  65. Orlowski RZ, Goldschmidt H, Cavo M. Phase III (IMROZ) study design: isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2018; 36(15 suppl):TPS8055. · DOI
  66. Laubach JP, Tuchman SA, Rosenblatt JM. Phase I, open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. EHA Library. 2020;EP953. · DOI
  67. Manasanch EE, Shah JJ, Lee HC. Bortezomib, lenalidomide, and dexamethasone with panobinostat for frontline treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. Lancet Haematol. 2018; 5(12):e628-e640. · DOI
  68. Kaufman JL, Mina R, Shah JJ. Phase 1 trial evaluating vorinostat plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020; 20(12):797-803. · DOI
  69. Kaiser MF, Hall A, Walker K. Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): results of the UK Optimum/MUKnine trial. J Clin Oncol. 2021; 39(15_suppl):8001. · DOI
  70. Stewart AK, Rajkumar SV, Dimopoulos MA. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2):142-152. · DOI · Paper page
  71. Gay F, Scalabrini DR, Belotti A. Updated efficacy and MRD data according to risk-status in newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclophosphamide: results from the FORTE trial. EHA Library. 2018;S109. · DOI
  72. Jakubowiak A, Chari A, Lonial S. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol. 2017; 35(15_suppl):8000. · DOI
  73. Waxman AJ, Clasen S, Hwang WT. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018; 4(3):e174519. · DOI · Paper page
  74. Shah C, Bishnoi R, Jain A. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018; 59(11):2557-2569. · DOI
  75. Shah JJ, Stadtmauer EA, Abonour R. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015; 126(20):2284-2290. · DOI
  76. Lakshman A, Kumar SK. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update. Am J Hematol. 2022; 97(1):99-118. · DOI
  77. San Miguel JF, Schlag R, Khuageva NK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-917. · DOI · Paper page
  78. Mateos MV, Richardson PG, Schlag R. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol. 2010; 28(13):2259-2266. · DOI
  79. Palumbo A, Bringhen S, Larocca A. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014; 32(7):634-640. · DOI
  80. Niesvizky R, Flinn IW, Rifkin R. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J Clin Oncol. 2015; 33(33):3921-3929. · DOI
  81. Mateos MV, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528. · DOI
  82. Mateos MV, Cavo M, Blade J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020; 395(10218):132-141. · DOI
  83. Facon T, Lee JH, Moreau P. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood. 2019; 133(18):1953-1963. · DOI
  84. Tacchetti P, Pantani L, Patriarca F. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematol. 2020; 7(12):e861-e873.
  85. Moreau P, Avet-Loiseau H, Facon T. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011; 118(22):5752-5758. · DOI
  86. Moreau P, Attal M, Hulin C. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192):29-38. · DOI
  87. Mai EK, Bertsch U, Durig J. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015; 29(8):1721-1729. · DOI
  88. Kumar SK, Facon T, Usmani SZ. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 MAIA study. Blood. 2020; 136(Suppl 1):24-26. · DOI

Cited by

Sorted by citations

Metadata

Authors
Richardson, P. G., Durie, B. G., Rosiñol, L., Mateos, M.-V., Dispenzieri, A., Moreau, P., Kumar, S., Raje, N., Munshi, N., Laubach, J. P., O’Gorman, P., O’Donnell, E., Voorhees, P., Facon, T., Bladé, J., Lonial, S., Perrot, A., & Anderson, K. C.
Affiliations
  • Harvard University (US)
  • Cedars-Sinai Medical Center (US)
  • Hospital Clínic de Barcelona (ES)
  • Mayo Clinic (US)
  • Centre Hospitalier Universitaire de Nantes (FR)
  • Massachusetts General Hospital (US)
  • University College Dublin (IE)
  • Levine Cancer Institute (US)
  • Université de Lille (FR)
  • Emory University (US)
  • Institut universitaire du cancer de Toulouse Oncopole (FR)
Corresponding author
Richardson, Paul G.
ORCID
Venue
Haematologica
Publisher
Ferrata Storti Foundation (Haematologica)
Published
2023-08-24
Volume
108
Issue
11
Pages
2894-2912
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
DOI
10.3324/haematol.2022.282624
PMC
PMC10620581
OpenAlex
W4386083642
Cited by
9
References
9
Citations by year
2026: 3 · 2025: 3 · 2024: 3
FWCI
1.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Haematologica (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Celgene
  • Regeneron Pharmaceuticals
  • National Cancer Institute (P50CA186781)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
newly diagnosed multiple myeloma, lenalidomide, bortezomib, dexamethasone, first-line therapy, maintenance therapy, transplant eligibility, drug toxicity, treatment guidelines
MeSH terms
Bortezomib, Lenalidomide, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Multiple Myeloma, Neoplasm Recurrence, Local

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review